TICKERNERD
Menu
TILTILHealthcare · Biotechnology

TIL Stock Forecast: Instil Bio, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$7.64
+2.83% on the day

The 1 Wall Street analysts covering Instil Bio, Inc. hold a median 12-month price target of $7 — -8.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$51.4M
Ticker Nerd rank
50 / 100
Median analyst target
$7.00
Analysts covering
1
Total return, dividends reinvested
1W
+3.5%
1M
+5.4%
YTD
−30.5%
1Y
−71.2%
From 52W high
−75.7%
From 52W low
+14.7%
$7
$32
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TIL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Instil Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
50 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
82
Accruals
73
Growth
70
Quality
60
Revisions
52
Issuance
42
Value
40
Volatility
25
Momentum
11

Size (82): Smaller than most of the companies we track.

Momentum (11): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TIL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TIL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26TILHigh $7.00Median $7.00Low $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Low $7.00Median $7.00High $7.00

The green dot is the last close — the median target sits −8.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Jan 2026HC Wainwright & Co.DowngradeNeutral—
11 Sept 2025HC Wainwright & Co.ReiteratesBuy—
27 Aug 2025HC Wainwright & Co.ReiteratesBuy—
15 Aug 2025HC Wainwright & Co.ReiteratesBuy—
5 June 2025HC Wainwright & Co.ReiteratesBuy—
2 June 2025JMP SecuritiesReiteratesMarket Perform—
23 May 2025HC Wainwright & Co.MaintainsBuy—
22 May 2025HC Wainwright & Co.MaintainsBuy—
5 Mar 2025HC Wainwright & Co.ReiteratesBuy—
13 Feb 2025JMP SecuritiesReiteratesMarket Perform—
7 Jan 2025JefferiesUpgradeBuy—
18 Nov 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024HC Wainwright & Co.MaintainsBuy—
4 Nov 2024JMP SecuritiesInitiatesMarket Perform—
17 Sept 2024HC Wainwright & Co.ReiteratesBuy—
16 Sept 2024BairdReiteratesOutperform—
16 Sept 2024HC Wainwright & Co.MaintainsBuy—
13 Sept 2024BairdMaintainsOutperform—
12 Sept 2024HC Wainwright & Co.MaintainsBuy—
23 Aug 2024HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TIL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

TIL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Instil Bio, Inc. (TIL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.7×

Cheaper than 81% of US stocks

Price / sales
—
Price / book
0.5×

Cheaper than 86% of US stocks

EV / EBITDA
−1.9×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−25.3%

Higher than 29% of US stocks

Return on assets
−10.8%

Higher than 26% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TIL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TILInstil Bio, Inc.$51.4M
50
TCRXTScan Therapeutics, Inc.$50.9M
37
IBOImpact BioMedical, Inc.$50.2M
24
APLMApollomics, Inc.$53.4M
16
ATYRaTyr Pharma, Inc.$49.2M
51
RNAZTransCode Therapeutics, Inc.$48.6M
23
HYPDHyperion DeFi, Inc.$48.2M
30

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Instil Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TIL news & analysis

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 13 Aug 2026neutral

Instil Bio reported its second quarter 2026 financial results and provided a corporate update. The company noted it is evaluating potential acquisitions, in-licensing, and related opportunities that could provide access to promising novel therapeutic candidates.

Why it matters — A TIL watcher would care because Instil's stated evaluation of acquisition and in-licensing opportunities signals potential strategic expansion of its pipeline beyond its current focus.

FAQ

Frequently asked questions about TIL stock

What is the TIL stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Instil Bio, Inc. have a median 12-month price target of $7, with estimates ranging from $7 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TIL stock a buy right now?

Of the 1 analysts covering Instil Bio, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Instil Bio, Inc. 50 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TIL?

As at 22 Aug 2026, Instil Bio, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (82 of 100).

Will TIL stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies -8.4% from the last close, and Ticker Nerd's factor model ranks Instil Bio, Inc. 50 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TIL stock forecast for 2030?

No analyst covering Instil Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TIL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $7 over the next 12 months.

How has TIL stock performed over the past year?

Instil Bio, Inc. returned -71.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Instil Bio, Inc. do?

Instil Bio, Inc. is a clinical-stage biotechnology company focused on the development of innovative cell therapies for the treatment of cancer.

What is the latest news on TIL?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update". Instil Bio reported its second quarter 2026 financial results and provided a corporate update. The company noted it is evaluating potential acquisitions, in-licensing, and related opportunities that could provide access to promising novel therapeutic candidates.

Company

About Instil Bio, Inc.

Instil Bio, Inc. is a clinical-stage biotechnology company focused on the development of innovative cell therapies for the treatment of cancer. Specializing within the pharmaceuticals and biotech sector, the company’s primary function is to research and advance next-generation immunotherapies, particularly those designed to harness and enhance patients’ own immune systems to target solid tumors. Instil Bio is notable for its work on tumor-infiltrating lymphocyte (TIL) therapies, as well as its proprietary bispecific antibody platforms. A key pipeline candidate, AXN-2510, is a PD-L1xVEGF bispecific antibody currently advancing through clinical trials, targeting relapsed or refractory solid tumors and non-small cell lung cancer (NSCLC). Founded in 2018, Instil Bio’s efforts impact the global healthcare market by seeking novel approaches to address cancers with unmet medical needs. The company’s research contributes to advancements in oncology and immunotherapy, sectors that are critical to the broader medical research and biopharmaceutical landscape. Instil Bio occupies a unique position among biotechnology peers, leveraging cutting-edge science to drive potential therapeutic breakthroughs in cancer care.

CEO Mr. Bronson Crouch · 17 employees · United States · https://instilbio.com